Tekmira expects $11.2M from Alnylam
Canada-based Tekmira Pharmaceuticals says that it expects to receive a minimum of $11.2 million over the next three years from its partner, US RNAi specialist Alnylam Pharmaceuticals, for process development and manufacturing services. This commitment is part of Tekmira's manufacturing relationship with Alnylam through Phase II clinical development for RNAi therapeutics that utilize the Canadian firm's SNALP technology, including Alnylam's clinical-stage product candidate ALN-VSP (Marketletter June 9, 2008). The manufacturing and development funding is in addition to ongoing research activities between the two companies and on top of any milestone payments that may be received from Alnylam.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze